ORTHOFIX MEDICAL INC. OFIX
- Market cap
- $373.1M
- P/E
- 0.0×
Follow OFIX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.51 | 33.51 | 48.00 | 39.75 | 22.11 | 28.65 | 13.76 | 9.57 | 12.08 | 10.24 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 48.25 | 56.53 | 63.57 | 74.44 | 47.91 | 48.50 | 36.13 | 23.19 | 20.73 | 20.48 |
High Price
|
|||
| 938 | 858 | 954 | 1,055 | 1,036 | 1,087 | 1,092 | 1,634 | 1,616 | 1,605 |
Employees
|
|||
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Revenue/Emp
|
|||
| 410 | 434 | 453 | 460 | 407 | 464 | 461 | 747 | 799 | 822 |
Revenue
|
|||
| 78.56% | 78.55% | 78.67% | 78.13% | 74.94% | 75.26% | 73.18% | 65.13% | 68.28% | 68.83% |
Gross Margin
|
|||
| 19 | 36 | 23 | (27) | 0 | (13) | (18) | (149) | (124) | (91) |
EBT
|
|||
| 4.64% | 8.39% | 5.05% | (5.88%) | (0.09%) | (2.91%) | (3.84%) | (19.91%) | (15.49%) | (11.04%) |
EBT Margin
|
|||
| 3 | 6 | 14 | (28) | 3 | (38) | (20) | (151) | (126) | (92) |
Net Income
|
|||
| 22 | 22 | 20 | 28 | 34 | 45 | 32 | 97 | 88 | 83 |
Depreciation
|
|||
| 22.59 | 23.95 | 24.50 | 24.33 | 21.10 | 23.59 | 22.97 | 20.33 | 20.97 | 20.76 |
Revenue/Sh
|
|||
| 0.17 | 0.34 | 0.73 | (1.51) | 0.13 | (1.95) | (0.98) | (4.12) | (3.30) | (2.33) |
Earnings/Sh
|
|||
| 3.26 | 2.15 | 2.70 | 1.69 | 3.85 | 0.94 | (0.58) | (1.25) | 0.68 | 0.84 |
Cash Flow/Sh
|
|||
| (1.01) | (0.91) | (0.90) | (1.09) | (1.26) | (0.99) | (1.15) | (1.69) | (0.91) | (0.87) |
Capex/Sh
|
|||
| 2.25 | 1.24 | 1.80 | 0.61 | 2.59 | (0.06) | (1.73) | (2.94) | (0.24) | (0.03) |
Free CF/Sh
|
|||
| 14.52 | 16.37 | 18.14 | 17.33 | 18.52 | 17.11 | 16.80 | 16.30 | 13.19 | 11.36 |
Book Value/Sh
|
|||
| 18 | 18 | 18 | 19 | 19 | 20 | 20 | 37 | 38 | 40 |
Shares
|
|||
| 209.00 | 160.41 | 71.90 | 0.00 | 330.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 1.57 | 2.28 | 2.14 | 1.90 | 2.04 | 1.32 | 0.93 | 0.65 | 0.83 | 0.73 |
PS Ratio
|
|||
| 2.45 | 3.33 | 2.89 | 2.66 | 2.32 | 1.82 | 1.27 | 0.81 | 1.32 | 1.33 |
PB Ratio
|
|||
| 1.49 | 2.14 | 2.03 | 1.79 | 1.86 | 1.18 | 0.87 | 0.75 | 0.95 | 0.85 |
EV/Sales
|
|||
| 15.72 | 49.20 | 29.11 | 82.69 | 15.65 | (187.64) | (10.83) | (5.06) | (66.79) | (193.86) |
EV/FCF
|
|||
| 59 | 39 | 50 | 32 | 74 | 18 | (12) | (46) | 26 | 33 |
Op' Cash Flow
|
|||
| (18) | (16) | (17) | (21) | (24) | (20) | (23) | (62) | (35) | (35) |
Capex
|
|||
| 41 | 22 | 33 | 12 | 50 | (1) | (35) | (108) | (9) | (1) |
FCF
|
|||
| 111 | 172 | 159 | 176 | 166 | 164 | 172 | 255 | 265 | 246 |
Working Cap'
|
|||
| — | — | — | 23 | 25 | 24 | 22 | 113 | 175 | 174 |
Total Debt
|
|||
| (54) | (81) | (72) | (48) | (72) | (64) | (29) | 75 | 89 | 89 |
Net Debt
|
|||
| 263 | 297 | 335 | 328 | 357 | 337 | 337 | 599 | 503 | 450 |
Sh' Equity
|
|||
| 0.79% | 1.60% | 3.17% | (5.92%) | 0.49% | (7.66%) | (4.22%) | (21.88%) | (13.86%) | (10.57%) |
ROA
|
|||
| 6.28% | 11.84% | 7.15% | (4.19%) | (1.37%) | (1.90%) | (2.70%) | (12.90%) | (8.93%) | (9.44%) |
ROIC
|
|||
| 1.10% | 2.22% | 4.37% | (8.59%) | 0.74% | (11.06%) | (5.86%) | (32.36%) | (22.87%) | (19.34%) |
ROE
|
|||
ORTHOFIX MEDICAL INC. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SI Shoulder Innovations, Inc. | $354.1M | 0.0× | Compare |
| VMD Viemed Healthcare, Inc. | $335.9M | 23.4× | Compare |
| CV CapsoVision, Inc. | $328.3M | 2.1× | Compare |
| CLPT ClearPoint Neuro, Inc. | $445.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TLSI TriSalus Life Sciences, Inc. | $303.6M | 0.0× | Compare |
| TMCI Treace Medical Concepts, Inc. | $295.3M | 0.0× | Compare |
| LAB Standard BioTools Inc. | $291.7M | 3.4× | Compare |
| SGHT Sight Sciences, Inc. | $478.2M | 0.0× | Compare |
ORTHOFIX MEDICAL INC. (OFIX) key facts
- ORTHOFIX MEDICAL INC. (OFIX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- ORTHOFIX MEDICAL INC.’s revenue for fiscal 2025 (year ended December 2025) was $822.3 million, up 2.85% from fiscal 2024.
- ORTHOFIX MEDICAL INC. reported a net loss of $92.2 million, or a loss of $2.33 per share, for fiscal 2025.
- As of September 25, 2026, OFIX traded at $9.44, a market capitalization of $373.1 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.5× sales.
- Return on equity was −19.3% and debt-to-equity 0.55.
ORTHOFIX MEDICAL INC. (OFIX) Latest News
24 Aug
Analysts trimmed Orthofix Medical's Q2 outlook, resulting in a fair value cut for OFIX stock. Trimmed Q2 outlook directly pressures near-term financial expectations and investor sentiment for Orthofix Medical.
15 Aug
Orthofix Medical experiences reimbursement rebound while spine business slump clouds outlook. Reimbursement gains balanced against spine decline point to moderate effects on operations and sentiment.
12 Aug
Orthofix Medical Inc. held its Q2 2026 earnings call, covering quarterly financial results, operational updates, and forward guidance for the orthopedic device business. Quarterly earnings and guidance typically affect near-term sentiment and valuation but rarely alter long-term company trajectory.
5 Aug
Orthofix Medical Inc raised guidance and outlined strategic moves in its Q2 2026 earnings call. Raised guidance and strategic moves signal major positive shifts in company trajectory and investor outlook.
Orthofix Medical Q2 earnings call highlighted financial results, operational updates, segment performance, and forward guidance. Q2 earnings highlights deliver financial and operational updates that may moderately shift near-term investor sentiment and valuation.
Orthofix Medical Inc. released Q2 2026 earnings results including revenue figures, segment performance, and forward guidance on product launches and cost management. Quarterly earnings provide updates on revenue and guidance that moderately influence near-term valuation and operations.
Orthofix Medical Inc. (OFIX) beat analyst estimates for both Q2 earnings and revenues. Q2 earnings and revenue beats typically support short-term stock gains without shifting long-term fundamentals.
Orthofix Medical Inc. reported second quarter 2026 results reflecting continued operational progress. Quarterly results update with operational progress signals moderately influences financial performance views and market sentiment.
23 Jul
CMS reversed its reimbursement decision for Orthofix Medical, improving the company's financial outlook and making its stock more attractive to investors. CMS reimbursement reversal directly improves Orthofix Medical revenue prospects and market trajectory.
18 Jun
Orthofix Medical (OFIX) stock faces split analyst revisions after CMS reimbursement reset. CMS reimbursement reset drives split analyst revisions that can significantly shift OFIX trajectory and investor sentiment.
4 Jun
CMS cuts and guidance changes reset Orthofix Medical narrative, pressuring future outlook and market performance. CMS cuts and guidance changes represent major regulatory shifts that significantly alter Orthofix Medical trajectory and investor sentiment.
16 May
Orthofix Medical resets its investment narrative after releasing new guidance and targets that adjust expectations for future performance and market positioning. New guidance and targets reset Orthofix Medical's investment story and are positioned to materially shift market expectations and company trajectory.
8 May
Orthofix Medical Inc. (NASDAQ:OFIX) just reported, and analysts assigned a US$17.25 price target. Analysts' US$17.25 price target after the report signals moderate influence on investor sentiment and stock performance.
6 May
Orthofix Medical Inc. (OFIX) expands its pediatric limb reconstruction portfolio with a new FITBONE™ innovation, showcased at the POSNA 2026 Annual Meeting. New FITBONE™ innovation expands pediatric limb reconstruction portfolio, signaling significant product advancement and potential market growth for Orthofix.
5 May
Orthofix Medical Inc. released Q1 2026 earnings call summary detailing first-quarter financial results, operational updates, and forward guidance. Q1 2026 earnings summary discloses key financial metrics and strategic outlook directly influencing stock trajectory and investor sentiment.
Orthofix Medical (OFIX) released Q1 2026 earnings call transcript detailing quarterly financial results, revenue growth, BioStim segment performance, operational updates, and forward guidance. Q1 earnings transcript discloses financial outcomes and guidance that significantly shape investor sentiment and stock trajectory.
Orthofix Medical Inc. (OFIX) released Q1 earnings call highlights, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights affect financial performance and investor sentiment but are routine quarterly updates.
Orthofix Medical Inc. (OFIX) reported first-quarter 2026 results, highlighting steady execution following spine commercial channel actions, and reaffirmed full-year 2026 financial guidance. Q1 results and reaffirmed full-year guidance demonstrate operational stability and financial predictability amid recent strategic adjustments.
25 Apr
Orthofix Medical (OFIX) narrative shifts following updated Q4 analyst models and 2026 guidance, signaling potential changes in growth outlook and investor perception. Q4 models and 2026 guidance represent major updates likely to significantly alter Orthofix Medical's trajectory and market sentiment.
9 Apr
Orthofix Medical Inc. (OFIX) realigns its spine leadership team to strengthen focus and execution. Spine leadership realignment targets improved focus and execution in a key segment, offering moderate operational benefits without transformative changes.
14 Mar
Orthofix Medical (OFIX) narrative shifts as analysts recut price targets and profitability timelines. Analyst revisions to price targets and profitability timelines moderately influence investor sentiment and expectations for OFIX's financial trajectory.
2 Mar
Canaccord Genuity reduced its price target on Orthofix Medical Inc. (OFIX) following the company's Q4 results and updated 2026 outlook. Analyst price target reduction post-Q4 results and 2026 outlook signals moderate negative impact on market sentiment and financial performance expectations.
26 Feb
Orthofix Medical (OFIX) investor narrative shifts due to delays in achieving targeted margins and release of new 2026 guidance. Margin delays and new 2026 guidance signal significant changes to Orthofix Medical's financial trajectory and investor sentiment.
24 Feb
Orthofix Medical Inc. released Q4 2025 earnings call summary detailing financial results, operational updates, strategic initiatives, and forward guidance. Q4 earnings results and guidance directly shape investor sentiment, financial outlook, and stock trajectory.
Orthofix Medical Inc (OFIX) reported strong sales growth and strategic advancements in Q4 2025 earnings call highlights. Strong sales growth and strategic initiatives in Q4 2025 earnings significantly enhance OFIX's financial performance and market positioning.
Orthofix Medical Inc. (OFIX) released Q4 earnings call highlights covering financial results, strategic updates, and future outlook. Q4 earnings call highlights detail financial performance, guidance, and strategies that significantly shape investor sentiment and company trajectory.
Orthofix Medical Inc. (OFIX) Q4 2025 earnings call transcript released, covering quarterly financial results, operational updates, and forward guidance. Q4 earnings transcript reveals financial performance and strategic outlook that significantly impact stock trajectory and investor sentiment.
Orthofix Medical Inc. (OFIX) released its Q4 earnings snapshot. Q4 earnings snapshots significantly impact Orthofix Medical Inc.'s financial performance, investor sentiment, and stock trajectory.
Orthofix Medical Inc. (OFIX) reported fourth quarter and full-year 2025 financial results, highlighting key performance metrics, and provided financial guidance for 2026. Releasing full-year financial results and issuing next-year guidance significantly impacts investor sentiment, stock valuation, and future market performance.
Orthofix Medical Inc. (OFIX) reported Q4 earnings and revenues that lagged behind analyst estimates. Q4 earnings and revenue shortfalls directly impact financial performance and short-term investor sentiment.